시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 뇌아밀로이드혈관병증 치료 시장 보고서(2025년)
Cerebral Amyloid Angiopathy Treatment Global Market Report 2025
상품코드 : 1720746
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,151,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 8,891,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,632,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

뇌아밀로이드혈관병증 치료 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 연간 평균 성장률(CAGR) 9.1%로 성장할 전망이며, 31억 9,000만 달러로 성장이 예측됩니다. 이 예측 기간 성장은 개별화 의료의 채택 증가, 바이오마커에 근거한 검출 방법 확대, 신경염증 치료 연구 진전, 신경질환 치료약 개발에 대한 투자 증가, 저침습 치료 옵션에 대한 기호 고조, 신경질환 연구에 대한 자금 제공의 확대 등에 기인하고 있습니다. 이 기간 주요 동향으로는 병용요법 모색, MRI 및 PET 영상진단의 주요 발전, 신흥국 시장에서의 헬스케어 인프라 확대, 저침습 치료법 개발, 제약기업과 바이오테크놀로지 기업의 제휴, 모니터링용 웨어러블 기술 채택 등을 들 수 있습니다.

신경 질환의 유병률 증가는 향후 수년간 뇌아밀로이드혈관병증 치료 시장의 성장을 가속할 것으로 예측됩니다. 신경 질환에는 뇌, 척수, 신경에 영향을 미쳐 운동, 감각, 인지, 기타 신체 기능에 장애를 초래하는 병세가 포함됩니다. 이러한 질환의 증가는 인구의 고령화, 라이프 스타일의 선택, 환경 요인, 유전적 소인, 진단 방법의 진보와 관련이 있습니다. 뇌아밀로이드혈관병증 치료는 혈관 내에 축적된 아밀로이드를 감소시켜 뇌 순환을 개선하고 인지기능 저하 및 뇌졸중과 관련된 합병증의 위험을 감소시킴으로써 신경질환 관리에 도움이 됩니다. 예를 들어 2023년 3월 미국의 비영리 임의건강단체인 알츠하이머병협회(Alzheimer's Association)는 65세 이상의 미국인 약 670만 명이 알츠하이머 치매를 앓고 있다고 보고했으며, 2060년까지 1,380만 명으로 증가할 것으로 예측하고 있습니다. 이러한 신경질환 유병률 증가가 뇌아밀로이드혈관병증 치료 시장 확대에 기여하고 있습니다.

또한 헬스케어 지출 증가도 뇌아밀로이드혈관병증 치료 시장의 성장에 기여할 것으로 예측되고 있습니다. 헬스케어 지출이란 개인, 정부, 조직에 의한 치료, 입원 치료, 의약품, 예방 조치 등의 의료 서비스에 할당되는 총 재원을 말합니다. 헬스케어 지출의 급증은 인구의 고령화, 만성 질환 이환율 상승, 의료 기술 진보, 헬스케어 서비스 및 치료에 대한 수요의 고조로 초래되고 있습니다. 뇌아밀로이드혈관병증 치료는 과녁을 좁힌 치료법 개발을 촉진하고 환자의 전귀를 개선하며 장기적인 케어 비용을 절감함으로써 헬스케어 자원의 효율적인 배분으로 이어져 헬스케어 지출에 일조하고 있습니다. 예를 들어 2023년 12월 미국 연방정부기관인 메디케어&메디케이드 서비스센터는 2022년 미국의 의료비가 4.1% 증가한 4조5,000억 달러에 달했으며, 2021년 기록한 3.2% 증가를 웃돌았다고 보고했습니다. 이 의료비 증가가 뇌아밀로이드혈관병증 치료 시장 확대에 박차를 가하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Cerebral amyloid angiopathy (CAA) treatment encompasses medical and therapeutic interventions designed to manage and mitigate the effects of CAA, a neurological disorder characterized by the accumulation of amyloid-beta proteins in the walls of cerebral blood vessels. This condition increases the risk of brain hemorrhages, cognitive decline, and dementia.

The primary types of CAA treatments include medication, therapeutic procedures, surgery, and supportive care. Medications are used to manage symptoms, slow disease progression, and treat associated conditions, administered through oral, intravenous, or intramuscular routes. These treatments are prescribed for various patient groups, including geriatric, adult, and pediatric populations, and are utilized across multiple healthcare settings such as hospitals, clinics, and homecare environments.

The cerebral amyloid angiopathy treatment market research report is one of a series of new reports from The Business Research Company that provides cerebral amyloid angiopathy treatment market statistics, including the cerebral amyloid angiopathy treatment industry global market size, regional shares, competitors with the cerebral amyloid angiopathy treatment market share, detailed cerebral amyloid angiopathy treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the cerebral amyloid angiopathy treatment industry. This cerebral amyloid angiopathy treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cerebral amyloid angiopathy treatment market size has grown strongly in recent years. It will grow from $2.06 billion in 2024 to $2.25 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth during the historic period can be credited to the rising prevalence of aging populations, increased awareness of cerebrovascular diseases, a surge in intracerebral hemorrhage cases, greater government funding for neurological research, reliance on symptomatic management, and the widespread use of MRI and neuroimaging for diagnosis.

The cerebral amyloid angiopathy treatment market size is expected to see strong growth in the next few years. It will grow to $3.19 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be credited to the increasing adoption of personalized medicine, expansion of biomarker-based detection methods, advancements in neuroinflammation treatment research, growing investments in neurological drug development, a rising preference for minimally invasive treatment options, and greater funding for neurological disorder studies. Key trends during this period include the exploration of combination therapies, advancements in MRI and PET imaging, expansion of healthcare infrastructure in emerging markets, development of minimally invasive treatments, collaborations between pharmaceutical and biotech firms, and the adoption of wearable technology for monitoring.

The increasing prevalence of neurological disorders is expected to drive the growth of the cerebral amyloid angiopathy treatment market in the coming years. Neurological disorders encompass medical conditions affecting the brain, spinal cord, or nerves, resulting in impairments in movement, sensation, cognition, or other bodily functions. The rising occurrence of these disorders is linked to aging populations, lifestyle choices, environmental factors, genetic predisposition, and advancements in diagnostic methods. Cerebral amyloid angiopathy treatment aids in managing neurological disorders by reducing amyloid buildup in blood vessels, improving cerebral circulation, and lowering the risk of cognitive decline and stroke-related complications. For example, in March 2023, the Alzheimer's Association, a US-based nonprofit voluntary health organization, reported that approximately 6.7 million Americans aged 65 and older were living with Alzheimer's dementia, with projections indicating a rise to 13.8 million by 2060. This growing prevalence of neurological disorders is contributing to the expansion of the cerebral amyloid angiopathy treatment market.

The increasing healthcare expenditure is also expected to contribute to the growth of the cerebral amyloid angiopathy treatment market. Healthcare expenditure refers to the total financial resources allocated to medical services, including treatments, hospital care, pharmaceuticals, and preventive measures by individuals, governments, and organizations. The surge in healthcare spending is driven by an aging population, a higher incidence of chronic diseases, technological advancements in medicine, and greater demand for healthcare services and treatments. Cerebral amyloid angiopathy treatment plays a role in healthcare spending by promoting the development of targeted therapies, improving patient outcomes, and reducing long-term care costs, leading to more efficient allocation of healthcare resources. For instance, in December 2023, the Centers for Medicare & Medicaid Services, a US-based federal agency, reported that U.S. healthcare spending grew by 4.1% in 2022, reaching $4.5 trillion, surpassing the 3.2% growth recorded in 2021. This rise in healthcare expenditure is fueling the expansion of the cerebral amyloid angiopathy treatment market.

Leading companies in the cerebral amyloid angiopathy treatment market are emphasizing the development of innovative products, such as RNAi therapeutics, to target disease-related gene expression and mitigate amyloid buildup in cerebral vessels. RNAi therapeutics represent a class of drugs that leverage RNA interference (RNAi) to silence specific genes, thereby preventing the production of disease-causing proteins. For instance, in July 2023, Alnylam Pharmaceuticals Inc., a US-based pharmaceutical company, announced plans to launch the multiple-dose phase of its ALN-APP clinical trial in approved regions. This trial is designed to evaluate the safety and efficacy of RNAi-based therapeutics in reducing amyloid precursor proteins (APP), which play a crucial role in amyloid plaque formation in the brain. By silencing the gene responsible for producing these proteins, the trial aims to determine whether ALN-APP can help prevent or even reverse the progression of cerebral amyloid angiopathy (CAA).

Major players in the cerebral amyloid angiopathy treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Limited, Merck & Co. Inc., Bayer AG, Novartis International AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Public Limited Company, Abbott Laboratories, GlaxoSmithKline plc, Medtronic PLC, Eli Lilly and Company, Boehringer Ingelheim International Limited, Viatris Incorporated, Biogen Idec Inc., Sandoz Group AG, Daiichi Sankyo Company Limited, Amneal Pharmaceuticals LLC, Lupin Limited, Glenmark Pharmaceuticals Limited, Alnylam Pharmaceuticals Incorporated, and Amydis Inc.

North America was the largest region in the Largest cerebral amyloid angiopathy treatment market in 2024. The regions covered in cerebral amyloid angiopathy treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cerebral amyloid angiopathy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cerebral amyloid angiopathy treatment market consists of revenues earned by entities by providing services such as diagnostic imaging services, genetic testing services, biomarker testing services, and therapeutic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cerebral amyloid angiopathy treatment market also includes sales of monoclonal antibodies, anti-inflammatory drugs, anticoagulants, antiplatelet therapy, and patient monitoring systems. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cerebral Amyloid Angiopathy Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cerebral amyloid angiopathy treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for cerebral amyloid angiopathy treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cerebral amyloid angiopathy treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Cerebral Amyloid Angiopathy Treatment Market Characteristics

3. Cerebral Amyloid Angiopathy Treatment Market Trends And Strategies

4. Cerebral Amyloid Angiopathy Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Cerebral Amyloid Angiopathy Treatment Growth Analysis And Strategic Analysis Framework

6. Cerebral Amyloid Angiopathy Treatment Market Segmentation

7. Cerebral Amyloid Angiopathy Treatment Market Regional And Country Analysis

8. Asia-Pacific Cerebral Amyloid Angiopathy Treatment Market

9. China Cerebral Amyloid Angiopathy Treatment Market

10. India Cerebral Amyloid Angiopathy Treatment Market

11. Japan Cerebral Amyloid Angiopathy Treatment Market

12. Australia Cerebral Amyloid Angiopathy Treatment Market

13. Indonesia Cerebral Amyloid Angiopathy Treatment Market

14. South Korea Cerebral Amyloid Angiopathy Treatment Market

15. Western Europe Cerebral Amyloid Angiopathy Treatment Market

16. UK Cerebral Amyloid Angiopathy Treatment Market

17. Germany Cerebral Amyloid Angiopathy Treatment Market

18. France Cerebral Amyloid Angiopathy Treatment Market

19. Italy Cerebral Amyloid Angiopathy Treatment Market

20. Spain Cerebral Amyloid Angiopathy Treatment Market

21. Eastern Europe Cerebral Amyloid Angiopathy Treatment Market

22. Russia Cerebral Amyloid Angiopathy Treatment Market

23. North America Cerebral Amyloid Angiopathy Treatment Market

24. USA Cerebral Amyloid Angiopathy Treatment Market

25. Canada Cerebral Amyloid Angiopathy Treatment Market

26. South America Cerebral Amyloid Angiopathy Treatment Market

27. Brazil Cerebral Amyloid Angiopathy Treatment Market

28. Middle East Cerebral Amyloid Angiopathy Treatment Market

29. Africa Cerebral Amyloid Angiopathy Treatment Market

30. Cerebral Amyloid Angiopathy Treatment Market Competitive Landscape And Company Profiles

31. Cerebral Amyloid Angiopathy Treatment Market Other Major And Innovative Companies

32. Global Cerebral Amyloid Angiopathy Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cerebral Amyloid Angiopathy Treatment Market

34. Recent Developments In The Cerebral Amyloid Angiopathy Treatment Market

35. Cerebral Amyloid Angiopathy Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기